繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
Eli Lilly and Co | 10-Q: Q3 2024 Earnings Report
Eli Lilly and Co | 10-Q: Q3 2024 Earnings Report
禮來 | 10-Q:2024財年三季報
牛牛AI助理已提取核心訊息
Eli Lilly and Co reported a significant increase in revenue for both the three and nine months ending September 30, 2024, with a 20% and 27% rise respectively compared to the same periods in 2023. The revenue for the quarter was $9,498.6 million, while the nine-month revenue reached $24,770.7 million. This growth was attributed to increased sales of Mounjaro, Zepbound, and Verzenio, despite a decline in Trulicity sales and the sale of rights for the olanzapine portfolio in 2023. Net income and diluted earnings per share saw a notable turnaround from a loss in the previous year to gains in the current period, with net income reaching $6,180.2 million and earnings per share at $6.83 for the nine months ended September 30, 2024. The improvement in net income and earnings per...Show More
Eli Lilly and Co reported a significant increase in revenue for both the three and nine months ending September 30, 2024, with a 20% and 27% rise respectively compared to the same periods in 2023. The revenue for the quarter was $9,498.6 million, while the nine-month revenue reached $24,770.7 million. This growth was attributed to increased sales of Mounjaro, Zepbound, and Verzenio, despite a decline in Trulicity sales and the sale of rights for the olanzapine portfolio in 2023. Net income and diluted earnings per share saw a notable turnaround from a loss in the previous year to gains in the current period, with net income reaching $6,180.2 million and earnings per share at $6.83 for the nine months ended September 30, 2024. The improvement in net income and earnings per share was primarily due to a higher gross margin, although this was partially offset by increased expenses in research and development, marketing, selling, administrative expenses, and charges related to asset impairment, restructuring, and other special items. Eli Lilly's financial performance indicates a robust growth trajectory, driven by successful product sales and effective cost management strategies. The company's business development has been marked by the strong performance of key products in its portfolio, which has contributed to the overall positive financial results. Looking ahead, Eli Lilly is likely to continue focusing on its late-stage pipeline developments and addressing the challenges within the industry to sustain its growth momentum.
禮來報告顯示,在2024年9月30日結束的三個月和九個月中,營業收入顯著增加,分別比2023年同期增長20%和27%。該季度營業收入爲$949860萬,而九個月的營業收入達到$2477070萬。增長歸因於蒙戈羅、澤普邦德和維舒尼歐銷量的提高,儘管2023年特盧利城銷售額下降,並且在2023年出售奧蘭扎平組合的權益。淨利潤和每股攤薄收益從上一年的虧損轉爲當期盈利,截至2024年9月30日的九個月,淨利潤達到$618020萬,每股收益爲$6.83。淨利潤和每股收益的改善主要歸因於較高的毛利率,儘管部分被研發、市場營銷、銷售、行政費用以及與資產減值、重組和其他特殊項目相關的費用的增加部分抵消。禮來的...展開全部
禮來報告顯示,在2024年9月30日結束的三個月和九個月中,營業收入顯著增加,分別比2023年同期增長20%和27%。該季度營業收入爲$949860萬,而九個月的營業收入達到$2477070萬。增長歸因於蒙戈羅、澤普邦德和維舒尼歐銷量的提高,儘管2023年特盧利城銷售額下降,並且在2023年出售奧蘭扎平組合的權益。淨利潤和每股攤薄收益從上一年的虧損轉爲當期盈利,截至2024年9月30日的九個月,淨利潤達到$618020萬,每股收益爲$6.83。淨利潤和每股收益的改善主要歸因於較高的毛利率,儘管部分被研發、市場營銷、銷售、行政費用以及與資產減值、重組和其他特殊項目相關的費用的增加部分抵消。禮來的財務表現表明出色的增長軌跡,得益於產品銷售的成功和有效的成本管理策略。該公司的業務發展以其組合中關鍵產品的強勁表現爲標誌,這些產品 contributed爲總體正面的財務結果。展望未來,禮來可能會繼續專注於其後期階段的管線開發,並應對行業內部的挑戰,以保持其增長動力。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間